website background - virtual.png

Highlights Speakers

Meet The Speakers


Daniel Hart

Dan Hart, M.D., Ph.D., is a consultant hematologist at The Royal London Hospital Haemophilia centre in the UK and senior lecturer in immunobiology at Barts and The London School of Medicine and Dentistry.


He is also the national hematology lead for the UK National Institute for Health Research.

His research group continues to examine mechanisms of alloreactivity to FVIII and together with colleagues, they have built a broad portfolio of clinical trial participation including  novel hemostatic agents and gene therapy.

khoo circle.png

Liane Khoo

Liane Khoo, M.D., is Director of the Haemophilia Centre and a Staff Specialist in Hematology at the Royal Prince Alfred Hospital in Sydney, Australia. She has served as principle investigator on numerous clinical trials in hemophilia and authored peer-reviewed journal articles and a book chapter.


In 2015 she won the John Lloyd Clinical Excellence Fund 2015 to undertake research on “Chromogenic FIX assay, application for use in a routine haemostasis laboratory” and in 2012 an award from the Haemophilia Foundation Research Fund to undertake research on “Monitoring recombinant FVIII concentrates: Xyntha and Kogenate Factor VIII Study.”


Midori Shima

Professor Shima is a head of the Thrombosis and Hemostasis Research Center in Nara Medical University. He has a long career in practicing clinical management for the patients with hemophilia. Furthermore, he has been involved in the basic, laboratory and clinical research over 35 years in the field of thrombosis and hemostasis. He has contributed to the development of FVIIIa mimicking bispecific antibody (Emicizumab). He has been a chairman of the Japanese Society on Thrombosis and Haemostasis (JSTH) since 2017. He has been elected to the ISTH Council Class of 2024. He is a one of the founders of the East Asia Hemophilia Forum (EAHF) and he has strong relationship with Asian Hemophilia Society.

Highlights 20 Banner - AP Bleeding 2.png
Suwanawiboon circle.png

Bundarika Suwanawiboon

Bundarika Suwanawiboon, M.D., is an Assistant Professor of Medicine at the Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. After graduating from the Faculty of Medicine Siriraj Hospital, Mahidol University, she obtained her Internal Medicine residency training at the University of Hawaii, Honolulu, Hawaii, and completed the Hematology-Oncology fellowship training at Duke University Medical Center, Durham, North Carolina.


Her interest in the field of hemostasis and thrombosis, including the prevention and treatment of venous thromboembolism, bleeding disorders, and complications of anticoagulant therapy.

zia circle.png

Ayesha Zia

Ayesha Zia, M.D., is a pediatric hematologist at the Children's Medical Center's Hemostasis Thrombosis Center, and the University of Texas Southwestern School of Medicine. Previous NHF (National Hemophilia Foundation) clinical fellowship award recipient, her clinical/translational research interests are geared toward pediatric patients with bleeding and clotting disorders. Zia also leads the multidisciplinary “Young Women’s Blood Disorders Clinic” at Children's Medical Center, focused on improving the care of adolescent girls with menorrhagia and bleeding disorders as well as girls with thrombophilia first and only program in North Texas that specializes in the diagnosis and treatment of bleeding and clotting disorders and accompanying reproductive problems in young women. 


Zia's current projects are focused on 1) elucidating the biology of hormonal induced thrombosis and predictors of thrombosis in young girls on oral contraceptives, 2) outcomes of thrombosis in the pediatric population including recurrent thrombosis and post-thrombotic syndrome, 3) Improving diagnostic strategies and quality of life in adolescent females with menorrhagia and bleeding disorders and 4) thromboprophylaxis in pediatric patients undergoing orthopedic surgeries. Zia is also the institutional co-investigator for several clinical trials investigating new treatments in hemostasis and thrombosis, including new medications for hemophilia, von Willebrand disease, and blood clots.